new version V2017

Nivolumab immune checkpoint inhibition
Description Results

Opdivo - BMS-936558 - ONO-4538 - MDX-1106      

  • Group by...

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

gastric or gastro-oesophageal junction cancer (advanced)

ATTRACTION-2, 2017nivolumabplacebo Low risk of bias SuggestingNCT02267343

Head and neck cancer

Checkmate-141, 2016nivolumabstandard treatment2L Risk of bias ConclusiveNCT02105636
Checkmate-651 ongoing nivolumab + ipilumabstandard treatment1L - NCT02741570

lung cancer (metastatic)

CheckMate 057, 2015nivolumabdocetaxel2L, non squamous Risk of bias SuggestingNCT01673867
CheckMate 017, 2015nivolumabdocetaxel2L, squamous Risk of bias SuggestingNCT01642004
CheckMate 026, 2016nivolumabplatinum-based CT1L, PDL1 positive Risk of bias NegativeNCT02041533
CheckMate 227 (High Tumor Mutational Burden), 2018nivolumab + ipilimumabplatinum-based CT1L, hi TMB Risk of bias SuggestingNCT02477826
CheckMate 227 (nivolumab + CT), 2018nivolumab + CTplatinum-based CT1L, PDL1 negatifSuggestingNCT02477826
CheckMate 331 ongoing nivolumabCT - NCT02481830
CheckMate 078 ongoing nivolumabdocetaxel - NCT02613507
CheckMate 153 ongoing nivolumab for 1 yearnivolumab2L Risk of bias - NCT02066636
Checkmate 032 ongoing nivolumab + ipilimumabnivolumab - NCT01928394
CheckMate 451 ongoing nivolumabplacebo - NCT02538666
CheckMate 722 ongoing nivolumab + ipilimumabplatinum-based CT Risk of bias - NCT02864251
CheckMate 227 (nivolumab alone), 2018 ongoing nivolumabplatinum-based CT1L Risk of bias - NCT02477826

melanoma

CheckMate 037 (Weber), 2015nivolumabchemotherapy2L, anti-CTLA-4 failure Risk of bias SuggestingNCT01721746
CheckMate 066 (Robert), 2015nivolumabdacarbazine1L Low risk of bias Conclusive NCT01721772
CheckMate 067 (nivo + ipi vs ipi), 2015nivolumab + ipilimumabipilimumab1L Low risk of bias Conclusive NCT01844505
Postow, 2015nivolumab + ipilimumabipilimumab1L Exploratory - NCT01927419
CheckMate 067 (nivo vs ipi), 2015nivolumabipilimumab1L Low risk of bias ConclusiveNCT01844505
CheckMate 067 (nivo + ipi vs nivo), 2015nivolumab + ipilimumabnivolumab1L Exploratory - NCT01844505
CheckMate 238, 2017nivolumabipilimumabadjuvant Low risk of bias ConclusiveNCT02388906

multiple myeloma

CheckMate 602 ongoing Nivolumab, Elotuzumab, Pomalidomide, dexaM Risk of bias - NCT02726581

renal-cell carcinoma (advanced)

Chekmate 025 (Motzer), 2015nivolumabeverolimus2L Risk of bias SuggestingNCT01668784
CheckMate-214, 2017nivolumab + ipilimumabsunitinib1L Risk of bias ConclusiveNCT02231749

urothelial carcinoma (advanced)

Checkmate 275nivolumabnil2nd line Exploratory - NCT02387996
CHECKMATE 901A ongoing nivolumab + CTchemotherapyfirst line Risk of bias - NCT03036098
CheckMate 274 ongoing nivolumabplacebofirst line Low risk of bias - NCT02632409
CHECKMATE 274A ongoing nivolumabplaceboadjuvant Low risk of bias - NCT02632409



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons